荷爾蒙補充療法(HRT)的全球市場:規模,佔有率,成長分析-療法各類型,各適應症,各給藥途徑-產業預測(2023年~2030年)
市場調查報告書
商品編碼
1286026

荷爾蒙補充療法(HRT)的全球市場:規模,佔有率,成長分析-療法各類型,各適應症,各給藥途徑-產業預測(2023年~2030年)

Global Hormone Replacement Therapy Market Size, Share, Growth Analysis, By Therapy Type, By Indication, By Route of Administration - Industry Forecast 2023-2030

出版日期: | 出版商: SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球荷爾蒙補充療法(HRT)的市場規模,2021年為249億7,000萬美金,從2022年的268億7,000萬美元,預計到2030年成為492億5,000萬美元。從2023年到2030年的預測期間內的年複合成長率成為7.83%。膽固醇值的上升,含血栓、脹感、腫等問題的副作用的可能性,抑制市場成長。

本報告提供全球荷爾蒙補充療法(HRT)市場的相關調查,市場概要,市場分析,企業簡介等全面性資訊。

目錄

摘要整理

親市場分析

  • 市場概要
  • 市場規模
  • 市場動態
  • 促進因素
  • 機會
  • 阻礙因素
  • 課題
  • 主要的市場洞察
  • 技術分析
  • 價格分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 知識產權分析
  • 貿易分析
  • Start-Ups分析
  • 原料分析
  • 革新矩陣
  • 開發中產品的分析
  • 宏觀經濟指標
  • 主要投資分析
  • 主要的成功因素
  • 競爭的程度
  • 市場動態與展望
  • 市場動態
  • 促進因素
  • 機會
  • 阻礙因素
  • 課題
  • 法規情形
  • 波特分析
  • 競爭企業間的敵對關係
  • 替代產品的威脅
  • 買方議價能力
  • 新加入業者的威脅
  • 供給企業談判力
  • 未來的混亂相關Skyquest的特別的洞察
  • 政治影響
  • 經濟影響
  • 社會影響
  • 技術影響
  • 環境影響
  • 法律影響
  • 全球荷爾蒙補充療法(HRT)市場:各療法類型
  • 市場概要
  • 雌激素、並用補充療法
  • 甲狀腺荷爾蒙補充療法
  • 成長荷爾蒙補充療法
  • 睪固酮荷爾蒙補充療法
  • 全球荷爾蒙補充療法(HRT)市場:各適應症
  • 市場概要
  • 閉經
  • 甲狀腺機能低下症
  • 男性的性腺功能降低症
  • 生長激素缺乏症
  • 全球荷爾蒙補充療法(HRT)市場:各給藥途徑
  • 市場概要
  • 口服
  • 經皮
  • 非口服
  • 全球荷爾蒙補充療法(HRT)市場規模:各地區
  • 市場概要
  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他的歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他的亞太地區
  • 南美
  • 巴西
  • 其他的南美
  • 中東、非洲
  • GCC各國
  • 南非
  • 其他的中東、非洲
  • 競爭情形
  • 主要5家公司的比較
  • 主要企業的市場上的定位(2021年)
  • 主要的市場參與企業採用的策略
  • 主要成功策略
  • 各開發
  • 各企業
  • 各年度
  • 市場上最近的活動
  • 主要企業的市場佔有率(%)(2021年)
  • 主要的企業簡介
  • Eli Lilly and Company(美國)
  • Bayer AG(德國)
  • Pfizer Inc.(美國)
  • Viatris, Inc.(美國)
  • Novo Nordisk A/S
  • Novartis International AG
  • Merck & Co. Inc.
  • Mylan N.V.
  • TherapeuticsMD Inc.
  • Abbott Laboratories
  • Allergan plc
  • Teva Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • AbbVie Inc.
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Ipsen S.A.
  • Sanofi S.A.
簡介目錄
Product Code: SQMIG35F2010

Hormone Replacement Therapy (HRT) Market size was valued at USD 24.97 billion in 2021 and is poised to grow from USD 26.87 billion in 2022 to USD 49.25 billion by 2030, growing at a CAGR of 7.83% in the forecast period (2023-2030).

For many years, women with menopause-related disorders have been successfully treated with hormone replacement therapy. As a result, the risk of osteoporosis has decreased, as have other menopause symptoms including hot flashes. Due to the development in additional hormone-related ailments that are targeted at different age groups and affect both women and men, these therapies are also causing the market to grow. Therefore, it is anticipated that over the projection period, conditions like thyroid disorders, growth deficits, and others would speed up market expansion on a global scale.

The hormone replacement therapy (HRT) industry is growing as a result of factors like the availability of long-acting hGH products and the rising prevalence of target disorders. According to the American Thyroid Association, thyroid disease will affect 12% of Americans at some point in their lives. Furthermore, it mentioned that roughly 20 million Americans have thyroid illness. According to numerous studies, people on HRT presumably had a low risk of COVID-19 infection and mortality.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormone Replacement Therapy (HRT) Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Global hormone replacement therapy (HRT) market is segmented based on therapy type, indication and region. Based on therapy type, the market is segmented into estrogen & combinations replacement therapy, thyroid hormone replacement therapy, growth hormone replacement therapy, testosterone hormone replacement therapy segments. On the basis of indication, the market can be bifurcated into menopause, hypothyroidism, male hypogonadism, growth hormone deficiency segments. Based on the route of administration, the market is segregated into oral, transdermal and parenteral route segments. The regional insights of the market are into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.

Driver

People with growth hormone deficiency, menopausal symptoms in women, and hypogonadism in the elderly are among the many people who require the therapy. The drug is available in a variety of forms, such as skin and buccal patches, injections, tablets, and others. Producers are focusing on developing innovative medicine delivery systems, such as transdermal oestrogen patches and vaginal oestrogen pills, as a result of the rising use of these products around the world. In line with the safety worries, they are focusing more on the introduction of low dose oestrogen therapy than high dose oestrogen therapy. The key competitors in the global market have also embraced the launch of gel-based formulations for items like oestrogen patches.

Restraint

Market expansion is being negatively impacted by some issues. Patches, gel, pills, and injections are just a few of the several therapeutic formulations available. However, these medications' possible adverse effects, which include an increase in cholesterol levels, blood clots, bloating, swelling, and other issues, may limit market growth.

Additionally, it is projected that the adverse effects of testosterone replacement therapy, such as benign prostatic hyperplasia, obstructive sleep apnea, and prostate cancer, may restrain market growth. Due to the rise in cardiovascular disorders among patients undergoing testosterone replacement therapy, the US FDA has also expressed concern regarding the approved indication and the increasing incidences of cardiovascular risks associated with the products used in testosterone replacement therapy.

Market Trends

The growth in unmet demand for hormone replacement therapy in emerging countries and the greater awareness of the treatment of hormone issues are driving pharmaceutical companies to continuously bring new cutting-edge pharmaceuticals to the global market. In addition, the prevalence of menopause and diseases linked to hormone deficiency in developed countries has led manufacturers to develop new products such combination treatment solutions in place of the long-acting parenteral drugs that were formerly used daily.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune
  • Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
  • Market Dynamics & Outlook
  • Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
  • Regulatory Landscape
  • Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
  • Global Hormone Replacement Therapy (HRT) Market by Therapy Type
  • Market Overview
  • Estrogen & Combinations Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Growth Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
  • Global Hormone Replacement Therapy (HRT) Market by Indication
  • Market Overview
  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Global Hormone Replacement Therapy (HRT) Market by Route of Administration
  • Market Overview
  • Oral
  • Transdermal
  • Parenteral
  • Global Hormone Replacement Therapy (HRT) Market Size by Region
  • Market Overview
  • North America
  • USA
  • Canada
  • Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
  • Latin America
  • Brazil
  • Rest of Latin America
  • Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA
  • Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
  • By Development
  • By Company
  • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
  • Key Company Profiles
  • Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Viatris, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • TherapeuticsMD Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Allergan plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Ferring Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
  • Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments